Bassim Marc K, Buss Emily, Clark Marcia S, Kolln Karen A, Pillsbury Carol H, Pillsbury Harold C, Buchman Craig A
Department of Otolaryngology, Neuroscience Hospital, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
Laryngoscope. 2005 Sep;115(9):1568-73. doi: 10.1097/01.mlg.0000171023.72680.95.
OBJECTIVE/HYPOTHESIS: Cochlear implantation is currently the treatment of choice for severe to profound sensorineural hearing loss. The MED-EL Combi40+ (Innsbruck, Austria) cochlear implant system was approved for use in the United States in 2001. This device employs a 31-mm-long electrode array, ceramic case, and continuous interleaved sampling with Hilbert transformation for envelope extraction. A single institution's experience with the Combi40+ implant in adult patients was reviewed.
Retrospective chart review.
Medical-surgical and audiological data were collected from 112 patients who received a MED-EL Combi40+ cochlear implant between December 1998 and April 2004.
The rate of surgical complications and speech perception testing results compared favorably with those of other cochlear implant systems. For postlingually deafened adults, mean CNC word, HINTQ, CUNY, and HINT + 10 dB signal-to-noise ratio scores after 1 year of implant usage were 54%, 87%, 96%, and 64%, respectively. Prelingually deafened adults also derived significant benefit, but plateau performance for these patients was well below that for patients with later onset of deafness and significant variability was seen in this group. Repeat implantation for suspected device malfunction was undertaken in seven cases (6% of devices) (mean duration of use, 28 +/- 12 mo) with ultimate resolution of the presenting problem.
The study results support the safety and efficacy of cochlear implantation with the MED-EL Combi40+ cochlear implant system.
目的/假设：人工耳蜗植入目前是重度至极重度感音神经性听力损失的首选治疗方法。MED-EL Combi40+（奥地利因斯布鲁克）人工耳蜗系统于2001年在美国获批使用。该设备采用31毫米长的电极阵列、陶瓷外壳，并通过希尔伯特变换进行连续交错采样以提取包络。回顾了单一机构在成年患者中使用Combi40+植入物的经验。
回顾性病历审查。
收集了1998年12月至2004年4月期间接受MED-EL Combi40+人工耳蜗植入的112例患者的医疗手术和听力学数据。
手术并发症发生率和言语感知测试结果与其他人工耳蜗系统相比具有优势。对于语后聋的成年人，植入使用1年后的平均CNC单词、HINTQ、纽约城市大学和HINT + 10 dB信噪比得分分别为54%、87%、96%和64%。语前聋的成年人也获得了显著益处，但这些患者的稳定表现远低于耳聋发病较晚的患者，并且该组存在显著变异性。7例（占设备的6%）（平均使用时长为28 +/- 12个月）因疑似设备故障进行了再次植入，最终解决了出现的问题。
研究结果支持使用MED-EL Combi40+人工耳蜗植入系统进行人工耳蜗植入的安全性和有效性。
